Related Experiment Video

Updated: Jun 11, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on

Gualberto Ruaño1, Paul D Thompson, John P Kane

  • 1Genomas, Inc, 67 Jefferson Street, Hartford, CT 06106, USA. g.ruano@genomas.net

Pharmacogenomics
|July 7, 2010
PubMed

Insights

Researchers identified genetic variations in the acetyl-coenzyme A carboxylase beta (ACACB) gene that influence low-density lipoprotein cholesterol (LDLC) levels during statin therapy. These findings may help personalize statin prescriptions to improve effectiveness and reduce side effects.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Genetics
  • Metabolic Research

Background:

  • Statins are commonly prescribed to lower low-density lipoprotein cholesterol (LDLC) in patients with hypercholesterolemia.
  • Individual responses to statin therapy, particularly regarding LDLC reduction, can vary significantly.
  • Genetic factors are hypothesized to contribute to this inter-individual variability in LDLC levels.

Purpose of the Study:

  • To investigate novel genetic underpinnings for variations in LDLC levels in patients undergoing statin therapy.
  • To identify specific single nucleotide polymorphisms (SNPs) associated with differential LDLC responses to statins.

Main Methods:

  • Genotyping of 384 SNPs across 222 genes in 202 volunteers from a lipid outpatient clinic.
  • Analysis of LDLC levels obtained from patient chart records.
  • Statistical analysis to identify significant associations between SNPs and LDLC levels, including correction for multiple testing.

Main Results:

  • Significant associations were found between LDLC levels and two SNPs in the acetyl-coenzyme A carboxylase beta (ACACB) gene: rs34274 (p < 0.0002) and rs2241220 (p < 0.008).
  • The rs34274 SNP (C>T substitution) was identified as a risk marker, while rs2241220 (C>T substitution) was identified as a protective marker for LDLC levels.
  • These SNPs are hypothesized to influence ACACB enzymatic activity through distinct mechanisms, affecting fatty acid metabolism.

Conclusions:

  • Physiogenomic evidence suggests a novel link between LDLC levels and the regulation of fatty acid metabolism via the ACACB gene.
  • These findings complement previous research on SNPs associated with statin-induced myalgia and myositis.
  • A physiogenomic model incorporating LDLC, myalgia, and myositis genotyping could optimize statin therapy effectiveness and minimize adverse effects.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...